A5082065479- Asthma and respiratory diseases
- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Urticaria and Related Conditions
- Respiratory and Cough-Related Research
- Pharmaceutical studies and practices
- Food Allergy and Anaphylaxis Research
- Autoimmune Bullous Skin Diseases
- Drug-Induced Adverse Reactions
- IL-33, ST2, and ILC Pathways
- Transgenic Plants and Applications
- Inhalation and Respiratory Drug Delivery
- Eosinophilic Esophagitis
- Contact Dermatitis and Allergies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Adrenal Hormones and Disorders
- Mast cells and histamine
- Stress Responses and Cortisol
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cholinesterase and Neurodegenerative Diseases
- Computational Drug Discovery Methods
- Cancer Immunotherapy and Biomarkers
- Medicinal Plants and Neuroprotection
- Immune Cell Function and Interaction
- Microscopic Colitis
Allergy, Asthma and Clinical Research Center
2015-2025
AbbVie (United States)
2022-2024
St. Vincent's Birmingham
2018-2023
Nationwide Children's Hospital
2023
Clinical Research Management
2020-2022
University of Alabama at Birmingham
2021
National Institute of Allergy and Infectious Diseases
1998-2000
Birmingham–Southern College
1996-1998
Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD).To assess the safety and efficacy dupilumab in patients with AD.This ongoing, multicenter, open-label extension study (NCT01949311) evaluated adults who had previously participated phase 1 through 3 clinical trials AD. This analysis examined given 300 mg weekly up 76 weeks at data cutoff (April 2016). Safety was primary outcome; also evaluated.Of 1491 enrolled (1042.9 patient-years), 92.9% were...
The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger exacerbations, induce release of IL-33, an epithelial-derived "alarmin." Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2. Approved biologic therapies for severe mainly benefit patients elevated blood eosinophils (type 2-high), but limited options are available low 2-low). Inhibiting signaling may target pathogenic pathways in wider...
For adolescent patients (aged ≥ 12 to < 18 years) with uncontrolled moderate-to-severe atopic dermatitis (AD), 16 weeks of treatment dupilumab resulted in substantial clinical benefit compared placebo, an acceptable safety profile. However, long-term data on the approved dose regimens adolescents AD are lacking. This open-label extension study (LIBERTY PED-OLE, NCT02612454) reports safety, efficacy, and pharmacokinetics who had participated parent trials. Patients enrolled under original...
Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited.To evaluate the efficacy safety of interleukin-13-targeted treatment tralokinumab monotherapy in AD.The 52-week, randomized, double-blinded, placebo-controlled, phase 3 ECZTRA 6 trial was conducted from July 17, 2018, through March 16, 2021, at 72 centers across 10 countries North America, Europe, Asia, Australia. Enrolled patients were 12 17 years old AD (Investigator's Global...
Background: Quilizumab, a humanized IgG1 monoclonal antibody, targets the M1-prime segment of membraneexpressed IgE, leading to depletion IgE-switched and memory B cells.In patients with mild asthma, quilizumab reduced serum IgE attenuated early late asthmatic reaction following whole lung allergen challenge.This study evaluated efficacy safety in adults allergic inadequately controlled despite high-dose inhaled corticosteroids (ICS) second controller.Methods: Five hundred seventy-eight were...
BackgroundPrimary (week 16) results from the ongoing phase 3, double-blind AD Up study (NCT03568318) demonstrate a positive benefit–risk profile for upadacitinib + topical corticosteroid (TCS) in patients with moderate-to-severe atopic dermatitis.ObjectiveWe evaluated efficacy and safety of TCS through 52 weeks.MethodsPatients aged 12 to 75 years chronic dermatitis (≥10% body surface area affected, Eczema Area Severity Index [EASI] ≥16, Validated Investigator's Global Assessment [vIGA-AD]...
Importance Atopic dermatitis onset usually occurs in childhood. Persistence of disease into adolescence and adulthood is common. It important to evaluate new treatment options adolescents because the high unmet need this population. Objective To assess efficacy safety upadacitinib treat moderate-to-severe atopic adolescents. Design, Setting, Participants Prespecified analysis enrolled 3 randomized, double-blind, placebo-controlled phase clinical trials more than 20 countries across Europe,...
Background LAVOLTA (L)I, LII, and ACOUSTICS were randomized, placebo-controlled, Phase 3 trials of lebrikizumab, a monoclonal antibody targeting interleukin-13, in patients with uncontrolled asthma. Failure to demonstrate efficacy may have been related patient selection those trials. Objective To assess the well-defined subpopulation elevated blood eosinophil counts minimum number prior asthma exacerbations. An additional analysis fractional exhaled nitric oxide (FeNO) exacerbations was...
Dupilumab has demonstrated efficacy with acceptable safety in clinical trials patients moderate to severe atopic dermatitis (AD).To assess dupilumab's impact on asthma and sinonasal conditions adult AD four randomized, double-blinded, placebo-controlled trials.In LIBERTY SOLO 1 (NCT02277743), 2 (NCT02755649), CHRONOS (NCT02260986), CAFÉ received placebo, dupilumab 300 mg every weeks (q2w), or weekly (qw). In CAFÉ, concomitant topical corticosteroids. This post hoc analysis assessed Asthma...
Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled standard-of-care therapy.To evaluate the long-term safety and re-treatment efficacy of ligelizumab 240 mg who completed core study extension study.This open-label, single-arm, Phase 2b was designed to assess were previously administered various doses ligelizumab, omalizumab or...
Introduction: Lebrikizumab, a novel, high-affinity monoclonal antibody selectively targeting interleukin-13, has demonstrated efficacy and safety in moderate-to-severe atopic dermatitis at higher doses than studied asthma. Clinical trials of lebrikizumab uncontrolled asthma have not consistent exacerbation reductions, possibly due to suboptimal patient selection premature understanding phenotypes. We describe post-hoc analyses adults with eosinophilic history ≥1 the past 12 months from 2...
Introduction: In ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA®, Dermavant Sciences, an Organon Company) once daily (QD) demonstrated superior efficacy was well tolerated in patients down to age years with atopic dermatitis (AD). We present efficacy, safety, tolerability from 3. Methods: Patients 2, a 4-week maximal usage pharmacokinetics trial, tapinarof-naive mild AD, or moderate severe that did not meet inclusion criteria, received QD for up 48 weeks. Endpoints included...
Patients with chronic urticaria (CU) may have different clinical courses of disease including periods active CU, remission, and relapse. The objective this study was to describe representative remission relapse profiles for patients CU. Adults a CU diagnosis confirmation diagnosis/CU-related treatment at least 6 weeks later were identified in the Optum® de-identified Electronic Health Record dataset (2007–2018). Active period during which patient not remission. Clinical defined as 12 months...